Abstracts tagged "anti-TNF therapy"

Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jennie Best⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…
Abstract Number: 1312 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Male Patients Using Anti-Tumor Necrosis Factor Alpha Patients with Inflammatory Arthritis; Hur-BIO Real Life Experiences
Oguz Abdullah Uyaroglu¹, Emrah Seyhoglu¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Alper Sari², Omer Karadag³, Ali Akdogan², Sule Apras Bilgen³, Sedat Kiraz², Ihsan Ertenli³ and Umut Kalyoncu³, ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: A significant part of patients with inflammatory arthritis are at their reproductive ages. Anti-tumor necrosis factor-alpha (Anti-TNF) agents are one of the relevant treatment…
Abstract Number: 2462 • 2017 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Rheumatoid Arthritis: A Retrospective Study
Ayse Hacioglu¹, Gulen Hatemi², Sinem Nihal Esatoglu², Yesim Ozguler², Serdal Ugurlu¹, Emire Seyahi², Melike Melikoglu², Izzet Fresko², Huri Ozdogan², Sebahattin Yurdakul² and Vedat Hamuryudan², ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Current guidelines on RA treatment recommend tapering of biologic DMARDs for patients in persistent remission. Methods: In this retrospective study we used the hospital…
Abstract Number: 1456 • 2017 ACR/ARHP Annual Meeting
Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Christian Secchi^1,2,3, Karen M. Doody², Mattias N. D. Svensson^2,4, Frances Humby⁵, Rebecca Hands⁵, Eugenio Santelli^1,2, Cristiano Sacchetti^2,6, Kuninobu Wakabayashi⁷, Dennis J. Wu⁸, Ardita Aliko⁹, Piotr Mydel^9,10, Tsuyoshi Kasama⁷, David L. Boyle¹¹, Francesco Galimi¹², Michel L. Tremblay¹³, Gary S. Firestein⁶, Costantino Pitzalis⁵, Stephanie Standford^8,14 and Nunzio Bottini^2,4, ¹Medicine, University of California San Diego, San Diego, CA, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Medicine, National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁶Medicine, University of California San Diego, La Jolla, CA, ⁷Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ⁸University of California San Diego, San Diego, CA, ⁹University of Bergen, Bergen, Norway, ¹⁰Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ¹¹University of California San Diego, La Jolla, CA, ¹²National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ¹³Goodman Cancer Centre, McGill University, Montréal, QC, Canada, ¹⁴La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose: Despite the availability of immunosuppressive disease-modifying anti-rheumatic agents (DMARDs), many rheumatoid arthritis (RA) patients still fail to achieve remission. Fibroblast-like synoviocytes (FLS) are non-immunological…
Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
B Haraoui¹, Janet E. Pope², Isabelle Fortin³, Emmanouil Rampakakis⁴, John S. Sampalis^5,6, Francoise Romeyer⁷, Joseph Atallah⁷ and Louis Bessette⁸, ¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷Bristol-Myers Squibb, Montreal, QC, Canada, ⁸Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada
Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting
Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden
Anders Gülfe¹, Tor Olofsson¹, Jonas K Söderling², Martin Neovius² and Johan K Wallman¹, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…
Abstract Number: 1520 • 2017 ACR/ARHP Annual Meeting
Golimumab Retention Rate in Patients with Spondyloarthitis. Differences between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Julia Martínez-Barrio⁴, Juan Gabriel Ovalles-Bonilla⁵, Juan Carlos Nieto², Iustina Janta², Larissa Valor³, Francisco Javier López Longo⁶ and Indalecio Monteagudo², ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in spondyloarthritis (SpA) has been widely documented. The aim of this study was to analize the long-term retention…
Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting
Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Mark C. Genovese¹, Josephine Glover², Nobuhito Matsunaga³, Diane Chisholm⁴ and Rieke Alten⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, ³Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, ⁴Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, ⁵University Medicine Berlin, Berlin, Germany
Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
Abstract Number: 287 • 2017 ACR/ARHP Annual Meeting
Anti-TNF Agents Induce Alternative Macrophages
Yannick Degboé¹, Benjamin Rauwel², Michel Baron², Jean Frédéric Boyer², Alain Cantagrel², Arnaud Constantin³ and Jean-Luc Davignon², ¹Centre de Physiopathologie Toulouse Purpan, INSERM UMR 1043, Toulouse, France, ²CPTP, INSERM UMR 1043, Toulouse, France, ³Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France
Background/Purpose: Macrophages contribute to the pathogenesis of rheumatoid arthritis (RA). They can display various states of activation or « polarization », characterized by distinct functions…
Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Atul A. Deodhar¹, Kevin Winthrop², Benjamin Chan², Sarah A. R. Siegel², Lisa Pisenti³, Jeffrey Stark³, Robert Y. Suruki⁴, Rhonda L. Bohn⁴, Huifeng Yun⁵, Lang Chen⁵ and Jeffrey R. Curtis⁵, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Raleigh, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…
Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting
Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Daniel J Lovell¹, Sarah Ringold² and P. Scott Eastman³, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Seattle Children's Hospital, Seattle, WA, ³Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA
Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting
Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden
Tor Olofsson¹, Johan K Wallman², Maria EC Schelin³, Anna Jöud⁴ and Jon Lampa⁵, ¹Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ³Lund University, Department of Clinical Sciences Lund, Oncology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Department of Laboratory Medicine Lund, Division of Occupational and Environmental Medicine, Lund, Sweden, Lund, Sweden, ⁵Karolinska Institute, Department of Medicine, Rheumatology Unit, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…
Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting
Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial
Atul A. Deodhar¹, John D. Reveille², Eric K. H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²University of Texas McGovern Medical School, Houston, TX, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…
Abstract Number: 2881 • 2017 ACR/ARHP Annual Meeting
Pre-Existing Psoriasis Is Predictive for Clinical Relapse after Drug-Free Remission Induced By Therapy with Golimumab in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ³Rheumatology, Ghent University Hospital, GENT, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital, Gent, Belgium
Background/Purpose: The use of new treatment strategies in early stages of spondyloarthritis (SpA) makes it possible to achieve remission or low disease activity in more…
Abstract Number: 543 • 2017 ACR/ARHP Annual Meeting
Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo
I Mercedes-Núñez, E Tejada-Reyes, Y Cruz-Rojas, E Rodríguez-Bautista, R Munoz-Louis, V Rosario, R Peña-Blanco, T Valdez-Lorie and R Alba-Fériz, Rheumatology, Hospital Docente Padre Billini (HDPB), Santo Domingo, Dominican Republic
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune chronic disease with disability and deforms joints. After the introduction of biological therapies the prognosis of…

« Previous Page
1
…
5
6
7
8
9
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].